Danish study of 150,000 people shows semaglutide users need fewer rescue migraine drugs — but only women see the benefit.
Women taking semaglutide for weight loss used 8% fewer migraine rescue medications over the following year, according to a large Danish study tracking nearly 150,000 people. The effect was specific to women — men showed no change in their migraine drug use. This wasn't a small trial with hand-picked participants. Researchers tracked real prescription data from Denmark's national health registry, watching what happened when people started Wegovy.
The migraine benefit appeared gradually over months, not immediately, suggesting semaglutide's anti-inflammatory effects may be reducing the underlying triggers rather than just masking symptoms. Here's what matters: this only helped people who already had migraines, not prevented new ones from starting. And the 8% reduction, while modest, could mean fewer debilitating headache days for women who currently rely on rescue medications that can cause rebound headaches when overused.
The sex difference isn't random. Women experience migraines at three times the rate of men, largely due to hormonal fluctuations. If semaglutide's anti-inflammatory effects interact differently with female hormone cycles and pain pathways, this could explain why only women benefited. The gradual timeline also makes sense — meaningful inflammation reduction takes time, not days.
What You Can Actually Do Today
- Track your current migraine frequency and rescue medication use for two weeks to establish a baseline
- If you're considering semaglutide for weight loss and have regular migraines, discuss this potential side benefit with your doctor
- Focus on proven migraine triggers you can control: consistent sleep schedule, regular meals, and identifying your personal food triggers
This research is preliminary and semaglutide isn't approved for migraine treatment. Discuss medication changes with your healthcare provider.
